Huadong Medicine Co., Ltd

000963

CNE0000011S1

Huadong Medicine Co., Ltd. specializes in the development, manufacture and marketing of medical products and vaccines. The products are intended primarily for the treatment of tumors, immune disorders, endocrine disorders, orthopedic and traumatological disorders, digestive system diseases and viral diseases.

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Huadong Medicine Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

31.52 CNY

Average target price

49.17 CNY

Spread / Average Target

+56.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
HUADONG MEDICINE CO., LTD	-23.97%	7.62B
MCKESSON CORPORATION	+12.06%	68.18B
CARDINAL HEALTH, INC.	+5.16%	25.78B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+4.48%	7.99B
SINOPHARM GROUP CO. LTD.	-2.79%	7.88B
H. LUNDBECK A/S	-1.16%	4.48B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+20.68%	4.45B
EBOS GROUP LIMITED	-4.23%	3.89B
GALENICA AG	-4.19%	3.82B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+23.62%	3.69B

Pharmaceuticals Wholesale

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
31.52 ^CNY	+4.89%		+6.96%	-23.97%

Apr. 18	Huadong Medicine's 2023 Profit Jumps 14%	MT
Apr. 17	Huadong Medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Huadong Medicine's 2023 Profit Jumps 14%	Apr. 17	MT
Huadong Medicine Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 17	CI
China's first biosimilar Ozempic drug applies for approval	Apr. 03	RE
Huadong Medicine to Build 2 Billion Yuan Biopharma Innovation Center	Feb. 09	MT
Huadong Medicine to Invest 2 Billion Yuan in Biopharma Innovation Center	Feb. 08	MT
Huadong Medicine's 2023 Profit to Climb Up to 14.5%	Feb. 01	MT
Huadong Medicine Eyes Exclusive Marketing Rights for Cancer Drug Senaparib in China for 290 Million Yuan	Dec. 20	MT
Huadong Medicine's Unit Gains Chinese Drug Regulator's Nod to Trial Sirolimus Oral Solution	Dec. 06	MT
Chongqing Yuyan Pharmaceutical Co., Ltd. announced that it has received CNY 300 million in funding from Huadong Medicine Co., Ltd, Hangzhou State Capital Investment And Operations Co., Ltd., Hangzhou Gongshu State Investment Industry Development Co., Ltd.	Nov. 14	CI
Huadong Medicine's Unit, Partners to Invest in Pharmaceutical Firm	Nov. 14	CI
Huadong Medicine Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Huadong Medicine's Unit Gets Nod to Test Weight Management Drug; Shares Up 3%	23-09-15	MT
Huadong Medicine Enters Exclusive Licensing Agreement with Denmark’s MC2	23-09-01	MT
Huadong Medicine’s H1 Profit Rises 7%; EPS, Revenue Miss Forecasts	23-08-16	MT
Huadong Medicine Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-15	CI
Huadong Medicine Buys Rights to US Skincare Drug For $100 Million	23-08-14	MT
Arcutis Authorizes Huadong Medicine Unit to Manufacture, Commercialize Topical Roflumilast in China, Southeast Asia	23-08-10	MT
Huadong Medicine Registers Obesity Drug	23-07-05	MT
Huadong Medicine Unit Gets Nod to Conduct Trial on Tumor Drug	23-06-30	MT
Huadong Medicine Co., Ltd Implements Final Profit Distribution Plan of A Shares for 2022, Payable on 14 June 2023	23-06-08	CI
Huadong Medicine Gets Nod to Trial Diabetes Drug in China	23-05-18	MT
Huadong Medicine Gets US FDA's Nod for Trial of Diabetes Drug	23-05-17	MT
Huadong Medicine Unit's Maivatinib Tablets Included in Breakthrough Therapy Program	23-05-15	MT
Huadong Medicine Co., Ltd Approves Cash Dividend for 2022	23-05-09	CI
Huadong Medicine’s Q1 Profit Rises 7% as Revenue Jumps 13%	23-04-21	MT